Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Bench-to-bedside review: preventive measures for contrast-induced nephropathy in critically ill patients.

van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ.

Crit Care. 2005 Aug;9(4):361-70. Epub 2005 Jan 7. Review.

2.

N-acetylcysteine and other preventive measures for contrast-induced nephropathy in the intensive care unit.

Schultz MJ, Baas MC, van der Sluijs HP, Stamkot GA, Smit W.

Curr Med Chem. 2006;13(21):2565-70. Review.

PMID:
17017911
3.

[Contrast induced nephropathy].

Hörl WH.

Wien Klin Wochenschr. 2009;121(1-2):15-32. doi: 10.1007/s00508-009-1145-3. Review. German.

PMID:
19263010
4.

[Iodinated contrast agent-induced nephropathy].

Erley C.

Radiologe. 2007 Sep;47(9):761-7. Review. German.

PMID:
17823784
5.

Clinical significance and preventive strategies for contrast-induced nephropathy.

Sterling KA, Tehrani T, Rudnick MR.

Curr Opin Nephrol Hypertens. 2008 Nov;17(6):616-23. doi: 10.1097/MNH.0b013e32830f45a3. Review.

PMID:
18941356
6.

Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review.

Walker PD, Brokering KL, Theobald JC.

Pharmacotherapy. 2003 Dec;23(12):1617-26. Review.

PMID:
14695041
7.

Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.

Meschi M, Detrenis S, Musini S, Strada E, Savazzi G.

Crit Care Med. 2006 Aug;34(8):2060-8. Review.

PMID:
16763513
8.

Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study.

Huber W, Eckel F, Hennig M, Rosenbrock H, Wacker A, Saur D, Sennefelder A, Hennico R, Schenk C, Meining A, Schmelz R, Fritsch R, Weiss W, Hamar P, Heemann U, Schmid RM.

Radiology. 2006 Jun;239(3):793-804.

PMID:
16714461
9.

Contrast-induced kidney injury: focus on modifiable risk factors and prophylactic strategies.

Kagan A, Sheikh-Hamad D.

Clin Cardiol. 2010 Feb;33(2):62-6. doi: 10.1002/clc.20687. Review.

10.

Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).

Ng TM, Shurmur SW, Silver M, Nissen LR, O'Leary EL, Rigmaiden RS, Cieciorka M, Porter LL, Ineck BA, Kline ME, Puumala SE.

Int J Cardiol. 2006 May 24;109(3):322-8. Epub 2005 Jul 22.

PMID:
16039733
11.

Prevention of radiocontrast nephropathy.

Lin J, Bonventre JV.

Curr Opin Nephrol Hypertens. 2005 Mar;14(2):105-10. Review.

PMID:
15687835
12.

Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease.

Shavit L, Korenfeld R, Lifschitz M, Butnaru A, Slotki I.

J Interv Cardiol. 2009 Dec;22(6):556-63. doi: 10.1111/j.1540-8183.2009.00500.x. Epub 2009 Sep 2.

PMID:
19732281
13.

Contrast-induced nephropathy.

Rundback JH, Nahl D, Yoo V.

J Vasc Surg. 2011 Aug;54(2):575-9. doi: 10.1016/j.jvs.2011.04.047. Epub 2011 Jul 13. Review.

14.

Contrast-induced nephropathy: a review.

Sanaei-Ardekani M, Movahed MR, Movafagh S, Ghahramani N.

Cardiovasc Revasc Med. 2005 Apr-Jun;6(2):82-8. Review.

PMID:
16263365
15.

Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.

Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK.

Catheter Cardiovasc Interv. 2002 Nov;57(3):279-83.

PMID:
12410497
16.

Current trials of interventions to prevent radiocontrast-induced nephropathy.

Asif A, Garces G, Preston RA, Roth D.

Am J Ther. 2005 Mar-Apr;12(2):127-32. Review.

PMID:
15767830
17.

Preventing contrast-induced nephropathy with fenoldopam.

Hunter DW, Chamsuddin A, Bjarnason H, Kowalik K.

Tech Vasc Interv Radiol. 2001 Mar;4(1):53-6.

PMID:
11981789
18.

Strategies to reduce the risk of contrast nephropathy: an evidence-based approach.

Pannu N, Tonelli M.

Curr Opin Nephrol Hypertens. 2006 May;15(3):285-90. Review.

PMID:
16609296
19.
20.

Supplemental Content

Support Center